Actively Recruiting
Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon
Led by Minghui Li · Updated on 2024-11-20
120
Participants Needed
1
Research Sites
86 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a real-world case-control study conducted, with 120 CHB patients who received continuous treatment with PEG-IFN-α for more than 24 weeks as study subjects. Among them, the clinical cure group obtained through PEG-IFN-α treatment is the case group; The group that did not achieve clinical cure after PEG-IFN-α treatment was used as the control group, and the case group and control group were allocated cases in a 2:1 ratio. Collect blood samples from subjects as sequencing samples for candidate genes, use high-throughput sequencing technology to detect the whole genome of subjects, identify relevant genetic polymorphism that have predictive value for clinical cure of chronic hepatitis B treated with PEG-IFN-α, and establish a predictive model and calculation formula between gene polymorphism and the efficacy of PEG-IFN-α antiviral therapy.
CONDITIONS
Official Title
Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years, Han ethnicity, any gender
- Diagnosed with chronic hepatitis B according to guidelines, with HBsAg and/or HBV DNA positive for more than 6 months
- Received subcutaneous PEG-IFN-alpha treatment for at least 24 consecutive weeks
- Voluntarily signed informed consent before study start
You will not qualify if you...
- Co-infection with HCV, HDV, HIV, or Treponema pallidum
- Evidence of alcohol abuse, decompensated cirrhosis, liver tumors (including liver cancer or AFP >100 ng/ml), or autoimmune diseases
- Pregnant during PEG-IFN-alpha treatment
- Any other condition deemed unsuitable for the trial by the patient
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100015
Actively Recruiting
Research Team
W
Weihua Cao, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here